secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioAtla, Inc. (BCAB)
CIK:        0001826892
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000950170-24-123281
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAtla Q3 net loss narrows to $10.6M on $11M collaboration revenue; cash runway into early 2026
--------------------------------------------------------------------------------

- Q3 net loss $10.6M vs $33.3M in Q3 2023; R&D expenses fell to $16.4M from $28.4M.
- Cash and equivalents $56.5M at Sept 30, 2024, down from $111.5M at Dec 31, 2023.
- Ozuriftamab vedotin (CAB-ROR2-ADC) shows median OS ~9 months in heavily pretreated SCCHN; FDA supported pivotal trial design.
- Evalstotug (CAB-CTLA-4) + PD-1 produced tumor reduction in all 8 first-line melanoma patients, with 1 CR and 3 PRs.
- Worldwide license agreement for CAB-Nectin-4 TCE with Context Therapeutics for up to $133.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826892/000095017024123281/0000950170-24-123281-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826892/000095017024123281/bcab-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-123281

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer